相关临床试验
466
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1938
进行中（未招募）
2
0.4%
已完成
187
40.1%
Enrolling By Invitation
1
0.2%
尚未招募
7
1.5%
招募中
32
6.9%
终止
10
2.1%
Unknown
203
43.6%
撤回
24
5.2%
暂无批准数据
- A 40-year-old Israeli man with an extreme opioid dependence of approximately 130 pills daily was successfully detoxed in a single 20-minute noninvasive brain procedure at Rambam Health Care Campus. - The treatment uses Insightec's focused ultrasound technology to modulate the nucleus accumbens without heating or damaging tissue, targeting the brain's reward and craving circuitry. - One week post-treatment, the patient tested negative for opioids and reported a craving score of zero out of 10, with an unexpected cessation of heavy smoking and alcohol urges. - The procedure is part of an international multicenter trial across three U.S. centers and Rambam, with researchers calling it a potential platform for treating PTSD, OCD, depression, and other disorders.
- Israel's Health Ministry is monitoring a suspected Ebola case in a traveler returning from the Democratic Republic of Congo, with final test results expected within 48 hours. - The current outbreak, caused by the Bundibugyo virus, has resulted in 933 confirmed cases and 245 deaths in the DRC, plus 19 cases and 2 deaths in Uganda. - Unlike the Zaire strain, no approved vaccine or specific antiviral treatment exists for the Bundibugyo virus, making supportive care the primary intervention. - The WHO has declared the situation a public health emergency of international concern, though global risk remains assessed as low.
- XTL Biopharmaceuticals announced acquisition of Psyga Bio for 40% equity stake, positioning the company as a leading psychedelic biotechnology platform with seven approved Phase 2a clinical trials. - The transaction follows President Trump's April 18, 2026 Executive Order directing FDA to accelerate psychedelic therapy research and approval pathways for serious mental illness treatment. - Psyga operates a licensed GMP-ready manufacturing facility for psilocybin and ibogaine production, with a proprietary library of over 180 unique mushroom strains. - The deal includes milestone-based earnouts totaling 30% additional equity tied to clinical trial commencement, target achievement, and ibogaine commercialization partnerships.
- Raphael Pharmaceutical filed a provisional patent application with the USPTO for its THC-free and CBD-free cannabinoid platform to treat neutrophil-dominant autoimmune diseases including rheumatoid arthritis. - The company's proof-of-concept clinical study demonstrated significant improvements in pain, sleep quality, and overall well-being in RA patients over eight weeks with no reported adverse effects. - The patent application covers treatment applications for multiple autoimmune conditions including psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus, and gout. - The cannabinoid formulation showed reduction in DAS28 scores from high disease activity to moderate disease severity, with benefits becoming evident as early as week four of treatment.
- Rambam Health Care Campus has initiated the first trial of Intellia Therapeutics' CRISPR-Cas9 gene therapy for transthyretin cardiac amyloidosis (ATTR-CA), marking a shift toward treating non-hereditary diseases with gene editing. - The therapy targets liver cells to permanently disable the gene producing misfolded proteins that cause heart failure, offering potential one-time treatment for a condition affecting 5% of heart failure patients. - CRISPR gene editing is expanding beyond rare genetic diseases to treat age-related conditions, with promising trials also underway for high cholesterol using similar mechanisms.
